Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants are the standard of care for treating established VTE and for prophylaxis of VTE. Oral direct factor Xa inhibitors are the preferred class of anticoagulant, while vitamin K antagonists (VKAs), antiplatelets, and heparins are frequently prescribed drug classes. Severe cases of DVT or PE may require thrombolytics to promote clot lysis before transitioning to anticoagulation. This analysis of claims data provides a quantitative picture of prescribing patterns for newly diagnosed and recently drug-treated VTE patients in the United States.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed VTE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed VTE patients?
• How have direct oral factor Xa inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of VTE patients receive drug therapy within 730 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 730 days of diagnosis?
• What percentage of VTE patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Boehringer Ingelheim, Pfizer, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson Innovative Medicine, Bayer, Genetech

Key drugs: Dabigatran etexilate mesylate, argatroban, dalteparin sodium, enoxaparin sodium, heparin sodium, fondaparinux sodium, apixaban, edoxaban, rivaroxaban, warfarin, alteplase

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses